Managing Gallbladder Disease on Ozempic (semaglutide 0.5-2 mg): The HealthRX.com Step-by-Step Protocol

What the Ozempic label instructs

Ozempic is a once-weekly GLP-1 receptor agonist injection approved for type 2 diabetes, with maintenance doses of 0.5, 1 or 2 mg [1]. Its warnings section includes acute gallbladder disease, and the instruction is one sentence: if cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated [1]. The Rybelsus and Ozempic tablet label carries the same sentence [2].

That is where the gallbladder guidance ends. The same warnings section tells prescribers to discontinue Ozempic if pancreatitis is suspected, but the gallbladder line carries no matching instruction to stop, hold, reduce or restart treatment [1].

How often gallbladder problems turn up on Ozempic

The label states that in placebo-controlled trials cholelithiasis was reported in 1.5% of patients treated with Ozempic 0.5 mg and 0.4% treated with 1 mg, and that it was not reported in placebo-treated patients [1].

The label also lists cholecystitis and cholecystectomy among postmarketing reports, and states that frequency cannot be estimated from voluntary reports [1].

SELECT followed 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes, on semaglutide 2.4 mg or placebo for a mean of 39.8 months [5]. Gallbladder-related disorders were reported in 2.8% on semaglutide versus 2.3% on placebo (p=0.04), driven mainly by cholelithiasis at 1.4% versus 1.1%; cholecystitis was 0.6% in both groups [3]. Those are 2.4 mg data, a dose above the Ozempic maximum of 2 mg, not Ozempic 0.5 to 2 mg data.

Pooled analyses point the same way. Across 21 randomized trials including 99,599 patients, gallbladder disorders were 26% more common with GLP-1 receptor agonists than with control [4]. In a meta-analysis of nine trials of once-weekly semaglutide in adults with overweight or obesity and no diabetes, the odds ratio was 1.26 for gallbladder disorders and 2.06 for cholelithiasis [6]. A 2021 safety review concluded that semaglutide increases the risk of biliary disease, specifically cholelithiasis [7].

On Ozempic 0.5 to 2 mg

Ozempic starts at 0.25 mg weekly for 4 weeks, which is not a maintenance dose, then moves to 0.5 mg [1]. Further increases to 1 mg and then 2 mg happen only after at least 4 weeks on the current dose [1].

The gallbladder warning is written for the drug rather than for one strength, and the label's cholelithiasis figures are given for the 0.5 mg and 1 mg groups [1]. For 2 mg, the label describes a separate 40-week trial of 959 patients on 1 mg or 2 mg in which no new safety signals were identified [1].